Single-infusion rituximab slows RA development in at-risk patients

“According to the current treatment paradigm, treatment of RA is initiated after the clinical onset of the disease,” Paul P. Tak, MD, PhD, of the Amsterdam University Medical Center, told Healio Rheumatology. “With this approach only a small minority of patients achieve disease remission, which is the treatment goal, and many patients need chronic treatment with biopharmaceuticals or targeted small molecules.” To evaluate the effects of B-cell directed therapy in patients who are at risk for autoantibody-positive RA who never experienced inflammatory arthritis before,